Northern Trust
TXG icon

Northern Trust’s 10x Genomics TXG Stock Holding History

Northern Trust’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.9M Buy
1,144,027
+96,022
+9% +$2.52M 0.01% 1286
2026
Q1 		$22.2M Buy
1,048,005
+54,625
+5% +$1.09M ﹤0.01% 1610
2025
Q4 		$16.2M Sell
993,380
-45,883
-4% -$693K ﹤0.01% 1807
2025
Q3 		$12.1M Buy
1,039,263
+29,951
+3% +$391K ﹤0.01% 2004
2025
Q2 		$11.7M Buy
1,009,312
+460,280
+84% +$4.2M ﹤0.01% 1972
2025
Q1 		$4.79M Sell
549,032
-12,634
-2% -$159K ﹤0.01% 2425
2024
Q4 		$8.07M Sell
561,666
-31,923
-5% -$504K ﹤0.01% 2245
2024
Q3 		$13.4M Sell
593,589
-55,221
-9% -$1.14M ﹤0.01% 1889
2024
Q2 		$12.6M Buy
648,810
+56,948
+10% +$1.49M ﹤0.01% 1855
2024
Q1 		$22.2M Buy
591,862
+122,227
+26% +$5.37M ﹤0.01% 1518
2023
Q4 		$26.3M Sell
469,635
-2,450
-0.5% -$107K ﹤0.01% 1423
2023
Q3 		$19.5M Buy
472,085
+11,599
+3% +$603K ﹤0.01% 1561
2023
Q2 		$25.7M Buy
460,486
+3,835
+0.8% +$208K ﹤0.01% 1421
2023
Q1 		$25.5M Buy
456,651
+58,937
+15% +$2.75M 0.01% 1395
2022
Q4 		$14.5M Buy
397,714
+4,779
+1% +$156K ﹤0.01% 1760
2022
Q3 		$11.2M Buy
392,935
+6,341
+2% +$242K ﹤0.01% 1897
2022
Q2 		$17.5M Sell
386,594
-88,125
-19% -$4.57M ﹤0.01% 1623
2022
Q1 		$36.1M Buy
474,719
+5,285
+1% +$462K 0.01% 1265
2021
Q4 		$69.9M Sell
469,434
-50,359
-10% -$7.71M 0.01% 868
2021
Q3 		$75.7M Buy
519,793
+42,144
+9% +$7.24M 0.01% 806
2021
Q2 		$93.5M Buy
477,649
+68,786
+17% +$12.4M 0.02% 707
2021
Q1 		$74M Buy
408,863
+13,132
+3% +$2.27M 0.01% 834
2020
Q4 		$56M Buy
395,731
+107,242
+37% +$15.6M 0.01% 984
2020
Q3 		$36M Buy
288,489
+105,361
+58% +$11.1M 0.01% 1145
2020
Q2 		$16.4M Buy
183,128
+158,666
+649% +$12.4M ﹤0.01% 1777
2020
Q1 		$1.52M Buy
24,462
+1,777
+8% +$139K ﹤0.01% 3004
2019
Q4 		$1.73M Buy
22,685
+14,471
+176% +$870K ﹤0.01% 3205
2019
Q3 		$414K Buy
+8,214
New +$455K ﹤0.01% 3587

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust's TXG Position: Q2 2026 in Review

Northern Trust increased its 10x Genomics (TXG) stake by 9.2% in Q2 2026, buying an estimated $2.52M and bringing the position to 1,144,027 shares worth $43.9M. The position accounts for 0.01% of the portfolio, ranked #1286.

Northern Trust first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $93.5M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Northern Trust held 1,144,027 shares of 10x Genomics worth $43.9M as of Q2 2026.
  • Northern Trust bought 96,022 10x Genomics shares in Q2 2026, an estimated $2.52M.
  • 10x Genomics made up 0.01% of Northern Trust's portfolio in Q2 2026, its #1286 holding.
  • Northern Trust first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's 10x Genomics position peaked at $93.5M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.